Fibrates and Cardiorenal Outcomes

McCullough, Peter A.; Loreto, Michael J. Di

doi:10.1016/j.jacc.2012.06.058

Cited by 6 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the role of fibrates in patients with CKD has yet to be determined [54]. Investigators in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [55] randomly allocated [56] 795 participants with type 2 diabetes mellitus to either fenofibrate (200 mg daily) or placebo, with a median follow-up period of 5 years.…”

Section: Reviewmentioning

confidence: 99%

Lipid mediators in diabetic nephropathy

Srivastava

Shu

Koya

et al. 2014

Fibrogenesis Tissue Repair

View full text Add to dashboard Cite

The implications of lipid lowering drugs in the treatment of diabetic nephropathy have been considered. At the same time, the clinical efficacy of lipid lowering drugs has resulted in improvement in the cardiovascular functions of chronic kidney disease (CKD) patients with or without diabetes, but no remarkable improvement has been observed in the kidney outcome. Earlier lipid mediators have been shown to cause accumulative effects in diabetic nephropathy (DN). Here, we attempt to analyze the involvement of lipid mediators in DN. The hyperglycemia-induced overproduction of diacyglycerol (DAG) is one of the causes for the activation of protein kinase C (PKCs), which is responsible for the activation of pathways, including the production of VEGF, TGFβ1, PAI-1, NADPH oxidases, and NFҟB signaling, accelerating the development of DN. Additionally, current studies on the role of ceramide are one of the major fields of study in DN. Researchers have reported excessive ceramide formation in the pathobiological conditions of DN. There is less report on the effect of lipid lowering drugs on the reduction of PKC activation and ceramide synthesis. Regulating PKC activation and ceramide biosynthesis could be a protective measure in the therapeutic potential of DN. Lipid lowering drugs also upregulate anti-fibrotic microRNAs, which could hint at the effects of lipid lowering drugs in DN.

show abstract

Section: Reviewmentioning

confidence: 99%

Lipid mediators in diabetic nephropathy

Srivastava

Shu

Koya

et al. 2014

Fibrogenesis Tissue Repair

View full text Add to dashboard Cite

show abstract

“…To overcome this challenge, chemists can use topological indices to derive mathematical equations that provide valuable insights into the properties of fibrates. For more information on fibrates, please refer to sources [5,6].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Symmetry of Curvilinear Regression Models for Enhancing the Analysis of Fibrates Drug Activity through Molecular Descriptors

Wazzan

Özalan

2023

Symmetry

View full text Add to dashboard Cite

Quantitative structure-property relationship (QSPR) modeling is crucial in cheminformatics and computational drug discovery for predicting the activity of compounds. Topological indices are a popular molecular descriptor in QSPR modeling due to their ability to concisely capture the structural and electronic properties of molecules. Here, we investigate the use of curvilinear regression models to analyze fibrates drug activity through topological indices, which modulate lipid metabolism and improve the lipid profile. Our QSPR approach predicts the physicochemical properties of fibrates based on degrees and distances from topological indices. Our results demonstrate that topological indices can enhance the accuracy of predicting physicochemical properties and biological activities of molecules, including drugs. We also conducted density functional theory (DFT) calculations on the investigated derivatives to gain insights into their optimized geometries and electronic properties, including symmetry. The use of topological indices in QSPR modeling, which considers the symmetry of molecules, shows significant potential in improving our understanding of the structural and electronic properties of compounds.

show abstract

Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature

Ito¹

2015

Atherosclerosis

View full text Add to dashboard Cite

Fibrates and Cardiorenal Outcomes

Cited by 6 publications

References 12 publications

Lipid mediators in diabetic nephropathy

Lipid mediators in diabetic nephropathy

Exploring the Symmetry of Curvilinear Regression Models for Enhancing the Analysis of Fibrates Drug Activity through Molecular Descriptors

Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature

Contact Info

Product

Resources

About